Effectiveness and tolerance of topical nadifloxacin in the therapy of acne vulgaris (grade I-II): Results of a non-interventional trial in 555 patients

Journal of Applied Research

Volumn 9, Issue 3, 2009, Pages 44-51

  Schöfer, Helmut ^a   Göllner, Arno ^c   Kusche, Werner ^b   Schwantes, Ulrich ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b ACRO Clinical Research Services GmbH   (Germany)

^c Dr R Pfleger GmbH   (Germany)

Author keywords

Acne vulgaris; Interactions; Nadifloxacin; Tolerance; Topical treatment

Indexed keywords

ADAPALENE; AZELAIC ACID; BENZOYL PEROXIDE; DOXYCYCLINE; ISOTRETINOIN; MINOCYCLINE; NADIFLOXACIN; RETINOIC ACID;

ACNE VULGARIS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; SELF EVALUATION; SKIN EFFLORESCENCE; SKIN MANIFESTATION; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME;

EID: 73249139081     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gollnick H, Orfanos CE: Clinical assessment of acne. in Cunliffe WJ (ed): Acne. Hippokrates, Stuttgart 1993
2. Worret W-I, Fluhr JW: Acne therapy with topical benzoylperoxide, antibiotics and azelaic acid. JDDG 2006; 4:293-300
3. Nenoff P, Haustein UF, Hittel N: Activity of Nadifloxacin (OPC-7251) and Seven Other Antimicrobial Agents against Aerobic and Anaerobic Gram-Positive Bacteria Isolated from Bacterial Skin Infections. Chemotherapy 2004; 50:196-201
4. Nishijima S, Kurokawa I, Nakaya H: Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. J Infect Chemother 2002; 8:187-189
5. Bojar RA, Hittel N, Cunliffe WJ, Holland KT: Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49 Suppl 2: 164-167
6. Plewig G, Holland KT, Nenoff P: Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a double-blind phase III comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16: 48-55
7. BfArM: Empfehlung zur Planung und Durchführung von Anwendungsbeobachtungen. Bundesanzeiger. 1998; 229: 16884-16885.
8. Nenoff P: Acne vulgaris and bacterial infections: review of the topical quinolone nadifloxacin. Expert Rev. Dermatol. 2006; 1: 643-654
9. Wigger-Alberti W, Wilhelm D, Schwantes U, Wilhelm KP: A randomized, double-blind clinical study investigating the cumulative irritation potential of a nadifloxacin cream combined with an additional treatment of other topical anti-acne products in a 21 day open application test. Poster presented at the 17th European Academy of Dermatology and Venerology Congress, 17th-21st Sep 2008, Paris, France.
10. Gollnick HPM, Krautheim A: Topical Treatment in Acne: Current Status and Future Aspects. Dermatology 2003; 206: 29-36
11. Witte F: Hochwirksame topische Therapie mit Nadifloxacin. Kompendium Dermatologie 2006; 1: 14-15
12. Ross JI, Snelling AM, Carnegie E, Coates P, Cunlife WJ, Bettoli V, Tosti G, Katsambas A, Galvan Peréz del Pulgar JI, Rollman O, Török L, Eady EA, Cove JH: Antibiotic-resistant acne: lesson from Europe. Br J Dermatol 2003; 148: 467-478
13. Alba V, Urban E, Dominguez MA, Nagy E, Nord CE, Palacín C, Vila J: In vitro activity of nadifloxacin against several Gram-positive bacteria and analysis of the possibile evolution of resistance after 2 years of use in Germany. Int J Antimic Agents 2009; 33: 272-275
14. Jacobs MR, Appelbaum PC: Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. Expert Opin Pharmacother 2006, 7: 1957-1966
15. Oizumi N, Kawabata S, Hirao M, Watanabe K, Okuno S, Fujiwara T, Kikuchi M: Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus. J Infect Chemother 2001, 7: 191-194
16. Coates P, Vyakrnam S, Eady EA, Jones CE, Vove JH, Cuncliff WJ: Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002, 146: 840-848
17. Dreno B, Reynaud A, Moyse D, Habert H, Richet H: Erythromycin-resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001, 11: 549-553